'DURVIT': a phase-I trial of single low-dose durvalumab (Medi4736) IntraTumourally injected in cervical cancer: safety, toxicity and effect on the primary tumour- and lymph node microenvironment (Q58748531)
Jump to navigation
Jump to search
scientific article published on 12 September 2018
Language | Label | Description | Also known as |
---|---|---|---|
English | 'DURVIT': a phase-I trial of single low-dose durvalumab (Medi4736) IntraTumourally injected in cervical cancer: safety, toxicity and effect on the primary tumour- and lymph node microenvironment |
scientific article published on 12 September 2018 |
Statements
'DURVIT': a phase-I trial of single low-dose durvalumab (Medi4736) IntraTumourally injected in cervical cancer: safety, toxicity and effect on the primary tumour- and lymph node microenvironment (English)
J Rotman
E S Jordanova
T D de Gruijl
12 September 2018
12 September 2018
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference